

2010 Report from the ISBT Working Party on Rare Donors



The Working Party on Rare Donors membership represents 18 countries and all Working Party members are members of ISBT, Attendance at Formal Working Party meetings is strong.

Terms of Reference #1

To develop guidelines for standardization of listing, labeling, shipping, testing and reimbursement for rare donors blood

Actions: An International Forum on Donors with a Rare Pheno (geno) type was published in Vox Sanguinis. Working Party members responded and from the reports, a long list of red cell antigen types that were difficult to provide emerged (see figure below).

Discussion by the Working Party members resolved that use of the shipping form is critical to assessing and responding to the global needs for rare blood. The Working Party submitted an ISBT Foundation grant proposal that was approved in 2010 to communicate and gather information regarding international shipping outcomes. The project will begin in July 2010 utilizing a previously developed Shipping Outcome Form to collect the data on rare red cell units shipped between countries.

Terms of Reference #2

To provide a resource for providing ongoing information on matters related to rare blood

Actions: Publications and presentations on Rare Donor activities have been published and also posted on the ISBT website as a resource for ISBT members. In addition, presentations were made at the ISBT Regional Congress in Nagoya, and at ISBT Congress in Cairo. An informal meeting of the Working Party along with two guests (one of which was nominated and approved to be a member in 2010 and one is nominated for 2010) was held to review activities of the Working Party. A presentation was made to the ISBT Board of Directors at Nagoya ISBT Regional Congress in 2009 to inform them of the activities of the Working Party. The Chair was also invited and wrote a review for Current Opinions in Hematology titled How to Find, Recruit and Maintain Rare Blood Donors.

Terms of Reference #3

To develop and extend the liaison with the International Blood Group Reference Laboratory (Bristol, England), and thus assist blood services internationally to be aware of, and contribute to, the WHO International Donor Panel

Actions: A number of members updated or are in the process of updating their Rare Donor lists with the International Blood Group Reference Laboratory. A major effort was made to identify members with Rare Donor Programs in their country even if there was not a national program. We had added the following members in 2008: Dr. Heli Tankanen (Finland), France Noizat-Pirenne (France), Dr. Philippe Rouger (France), Dr Rita Fontao-Wendel (Brazil), Dr Erwin Andreas Scharberg (Germany). Dr K.Vasantha (India). This added two countries (Finland and India); the others were replacing retiring members. We added Dr Eduardo Muniz-Diaz and Mostafa Moghaddam from Spain and Iran respectively and replaced retiring members from Germany, New Zealand, Taiwan and The Netherlands with Dr Inge von Zabern, Dr Dhana Gounder, Dr Sujen in Tsai, Dr Masja de Haas respectively. Strategic member recruitment has been the objective of the executive committee with the intent of building the International Rare Donor Panel and building a network of knowledgeable members ready to help locally and globally.

Respectfully submitted,

Sandra Nance, MS, MT(ASCP)SBB
Chair, ISBT Working Party for Rare Donors

Country	Phenotypes difficult to provide
Austria	Rare Rh phenotypes with antibodies to high-prevalence antigens and other common antibodies
Brazil (Sao Paulo)	McLeod, Ko, Lan-, U-, RH29-, RH17-
Finland	Vel-, Ge:-2
France	U- D-, Hr ^{S-} , Hr ^{B-} , Js(b-), R ^N /R ^N , Rh _{null} , Jr(a-), Co(a-b-)
Germany	Fy(a-b-), In(b-), Ge:-2, -3, U-
China (Hong Kong)	Di(b-), Fy(a-b-), Jk:-3
Oman and India	D-, In(b-), Co(a-b-)
Israel	p, Jr(a-), O ^h , Ko, U-, Vel-, Lan-
Italy (Milan)	Sc:-1, Lw(a-), Ko, Jk:-3, U-, Di(b-)
Japan	Ge-, En(a-), M ^k M ^k , Lan-
The Netherlands	U- D-, Fy(a-b-), Lu(a-b-) D-, At(a-), Cr(a-)
New Zealand	D-, Ko, McLeod, p, Ge:-2, Js(b-), U-
Spain (Navarra)	Yt(a-), Co(a-), Js(b-), Lan-, Ge-, I-, Jr(a-), Br-
Switzerland	Kp(b-), Vel-, P ^k , Jk:-3, D-, Ko, Lan-
United Kingdom	Rh _{null} , Sc:-1, P ₁ ^k , Ge:-2, -3, D-, McLeod, U-

United States

At(s-), En(a-), Hy-, Ko, Cr(a-), Ge:-2, In(b-), Lan-, Di(b-)
Ge:-2, Jk:-3, Lu(a-b-), hr^{S-} E-, Gy-, Wes(b-),
especially when other common antibodies to antigens are present
